3. Refining the risk estimate for transfusion transmission of occult hepatitis B virus 9. Experiences with semi routine production of riboflavin and UV - B Pathogen 18. Platelet responses to ago…
219 erythropoietin to reduce allogenic red blood cell transfusion in patients undergoing total hip or knee arthroplasty 226 Investigation of bacterial inactivation in aphresis platelets with 24 or…
Transfusion transmited disease and its prevention Blood component collection and production Transfusion medicine and new therapies Cellular therapy International forum
Blood component collection and production Transfusion medicine and new therapies Cellular therapy International forum
Blood component collection and production Transfusion medicine and new therapies Immunohematology and immunogenetics
Blood component collection and production Transfusion medicine and new therapies Immunohematology and immunogenetics Cellular therapy Short report Letters to the editor
Transfusion transmitted disease and its prevenstion Blood component collection and production Transfusion medicine and new therapies international forum Letters to the editor
Local day donors and donation Clinical aspects Blood/blood components and products ISBT academy day practical approach to donors and donations/the spectrum of donors and donation Practical app…
Transfusion transmited disease and its prevention Blood component collection and production Transfusion medicine and new therapies Immunohematology and immunogenetics Cellular therapy